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Abstract
Introduction: To the best of our knowledge, we describe for the first time the case of a woman who met the
diagnostic criteria for fibromyalgia, did not respond to therapy for that disorder, and was subsequently diagnosed
by biochemical and genetic studies with a mitochondrial myopathy. Treatment of the mitochondrial myopathy
resulted in resolution of symptoms. This case demonstrates that mitochondrial myopathy may present in an adult
with a symptom complex consistent with fibromyalgia.
Case presentation: Our patient was a 41-year-old Caucasian woman with symptoms of fatigue, exercise
intolerance, headache, and multiple trigger points. Treatment for fibromyalgia with a wide spectrum of
medications including non-steroidal anti-inflammatory drugs, antidepressants, gabapentin and pregabalin had no
impact on her symptoms. A six-minute walk study demonstrated an elevated lactic acid level (5 mmol/L; normal <
2 mmol/L). Biochemical and genetic studies from a muscle biopsy revealed a mitochondrial myopathy. Our patient
was started on a compound of coenzyme Q10 (ubiquinone) 200 mg, creatine 1000 mg, carnitine 200 mg and folic
acid 1 mg to be taken four times a day. She gradually showed significant improvement in her symptoms over a
course of several months.
Conclusions: This case demonstrates that adults diagnosed with fibromyalgia may have their symptom complex
related to an adult onset mitochondrial myopathy. This is an important finding since treatment of mitochondrial
myopathy resulted in resolution of symptoms.
Introduction
Fibromyalgia is a condition characterized by chronic
widespread pain and fatigue which affects approximately
2% of the US population [1]. The diagnostic criteria
include pain lasting for longer than three months on
both sides of the body, involving the upper and lower
halves of the body, and presence of at least 11 out of 18
specific tender points over the body [2].
Over the years, several pathogenic mechanisms for the
condition have been postulated but the exact pathogen-
esis still remains a mystery. Historically, disordered
sleep [3], circadian rhythm abnormalities [4], and hor-
monal imbalance [5] have been looked upon as potential
causes, but whether these factors are important in the
pathogenesis, or merely arise secondary to bodily stress
remains unclear. Alteration in pain modulatory neuro-
peptides [6] is another widely studied hypothesis, but
several studies have shown variable results with no defi-
nitive conclusion. Finally, another more recent theory is
t h ep r e s e n c eo fu n d e r l y i n gm u s c l em e t a b o l i cd i s e a s e
that leads to abnormalities in high-energy phosphate
metabolites. Other postulated causative explanations
include genetic abnormalities, psychiatric disorders, and
environmental stressors [7].
Furthermore, due to our lack of understanding of this
condition, treating fibromyalgia has always been a chal-
lenge for most clinicians. Subsequently, several different
groups of medications have been tried over the years.
Historically, tricyclic antidepressants have been the most
commonly used medications and although short-term
studies did show some benefit in some patients, long-
term prospective studies failed to reveal any significant
effect [8].
Other medication groups used to treat fibromyalgia
include selective serotonin reuptake inhibitors (SSRIs)
and serotonin-norepinephrine reuptake inhibitors
(SNRIs), anticonvulsants, opioid analgesics, sedatives,
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able responses have been observed, the benefits have
been largely unsatisfactory, and patients are all too often
exposed to the numerous, potentially lethal side effects
of common medications. Generally, only a small group
of patients respond, and most people do not have long-
term benefit [9].
We present the case of a patient in whom the symp-
toms of fibromyalgia were related to an underlying
mitochondrial disorder. Treatment of the mitochondrial
disorder resulted in resolution of symptoms.
Case presentation
Our patient was a 41-year-old Caucasian woman who
presented to our Rheumatology clinic for evaluation of
progressive exercise intolerance, fatigue, diffuse myal-
gias, arthralgias and difficulty sleeping. The pain primar-
ily involved her entire back and arms, and she reported
multiple tender points all over her body. On the basis of
her symptoms, our patient had also been diagnosed with
fibromyalgia, and was treated with multiple different
medications without any relief.
Her other medical history included hypothyroidism,
cervical disc disease, hypertension and Raynaud’sd i s -
ease. Notable family history included breast carcinoma
and hypertension in her mother, and lymphoma in her
father. Her medications at presentation included lisino-
pril 5 mg daily and levothyroxine 25 μg daily. Other
pertinent medications she had previously used included
pregabalin, amitriptyline and gabapentin. Her physical
examination results were normal except for mild tender-
ness to palpation along her upper and lower back, and
shoulders.
Significant laboratory results included creatine kinase
(CK) = 325 U/L (normal range 0 to 150 U/L), normal
comprehensive metabolic panel (CMP) and complete
blood count (CBC), liver function tests and thyroid
functions tests. A six-minute walk test revealed a nor-
mal resting lactic acid = 1.6 mmol/L, and an elevated
post-six-minute-walk lactic acid = 5 mmol/L (normal
result < 2 mmol/L). Her ammonia levels were normal
at rest and after six-minute walk (14 μmol/L and 38
μmol/L respectively; normal 0 to 40 μmol/L). A muscle
biopsy was performed for biochemical evaluation,
which revealed several abnormalities including
decreased levels of citric acid synthase (49% of nor-
mal), cytochrome c oxidase (53% of normal), succinate
dehydrogenase (72% of normal), and nicotinamide ade-
nine dinucleotide (NADH) dehydrogenase (73% of nor-
mal), thereby demonstrating a defect in the
mitochondrial respiratory chain. Genome sequencing
was performed, which revealed multiple POLG1 poly-
morphisms (C-T polymorphism at 2254, and G-T
polymorphism at 3708) and several mitochondrial
genome polymorphisms (1438 A-G, 3992 C-T, 14365
C-T, 14582 A-G, and 4042 A-G).
Our patient was started on a compound of Co-Q10
200 mg, creatine 1000 mg, carnitine 200 mg and folic
acid 1 mg to be taken four times a day. She gradually
showed significant improvement in her symptoms over
a course of several months.
Discussion
Mitochondrial myopathies are disorders characterized by
morphological abnormalities of muscle mitochondria.
Accumulating evidence suggests that mitochondrial dis-
orders are among the most common inherited metabolic
diseases [10]. Similar to fibromyalgia, patients may pre-
sent with muscle weakness, pain, fatigue and exercise
intolerance that progressively worsens over time.
Several steps are involved in Adenosine-5’-tripho-
sphate (ATP) generation in the mitochondria, and
defects in any part of the cycle may impair energy pro-
duction leading to symptoms [11]. These abnormalities
in generation and utilization of ATP can be assessed by
specific tests, which as in our patient pointed towards
problems in energy metabolism [12]. Genetic testing
with sequencing of the mitochondrial genome and chro-
mosomal genes affecting mitochondrial function may
also be pursued, as was performed in our patient. Muta-
tions in POLG1 and several mitochondrial genome poly-
morphisms were noted.
Subsequently, our patient was started on a regimen of
coenzyme Q10 (Co-Q10; ubiquinone), creatine, carni-
tine, folic acid and a-lipoic acid. Co-Q10 transports
electrons between complex I and complex III of the
mitochondrial respiratory chain and has been shown to
improve mitochondrial function in several studies [13].
Creatine generates additional ATP through the creatine
phosphate shuttle. Carnitine enhances transport of fatty
acids into the mitochondria. Folic acid is a cofactor for
several mitochondrial enzymes, while a-lipoic acid is a
strong antioxidant [14]. Although this treatment regi-
men was started several years after symptom onset,
within the first few months our patient showed tremen-
dous improvement. With continued therapy, her com-
plaints dissipated over several months, with a gradual
but sustained resolution of all symptoms.
Conclusions
This case postulates the possible role of mitochondrial
disease in the pathogenesis of the symptom complex
known as fibromyalgia, whereby not only is the underly-
ing defect identified at the molecular and genomic level,
but with appropriate therapy, significant symptomatic
improvement is also noted.
Underlying mitochondrial disease may not be the only
explanation for such a symptom complex, but the exact
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fibromyalgia needs to be studied further for a better
understanding of the disease, and to ensure adequate
and effective patient care. All patients with fibromyalgia
should be evaluated for sleep disorders, endocrine disor-
ders such as hypothyroidism and metabolic disorders
before a diagnosis of primary fibromyalgia is given. The
relative frequency of these medical problems in patients
currently diagnosed with fibromyalgia is unclear, but
would be worthy of future study.
Patient’s perspective
I am pleased to contribute to this article as to help
others with a similar problem. I am truly grateful to Dr
Julian Ambrus Jr and to those who referred me to his
expert care.
I am a 44-year-old woman with mitochondrial myopa-
thy confirmed by blood tests and muscle biopsy. This
disease grew worse as I aged and was exacerbated by
pregnancy and other stressors. Certain medications
really made me feel ill (which I now know to be mito-
chondrial killers). My main symptoms included muscle
and joint pain, weakness, fatigue, muscle twitching, pain,
headaches, and visual disturbances.
I have been to several doctors and have had several
tests to rule out certain diseases. This process was slow
and frustrating knowing I was sick and not having a
clear answer. I was diagnosed with fibromyalgia, but
there were other symptoms as well. My feet, hands and
legs were weak to where I fell several times down stairs
and in my home. I was too weak to hold dishes and to
wash them. Simple daily chores proved difficult, and at
times I could not get out of bed or a chair without help.
The fibromyalgia medicines did not help. As my symp-
toms waxed and waned, time and rest helped a bit. I
was concerned that in time I would get progressively
worse.
Today however, I am happy to say that I am feeling
much better and able to enjoy normal activities again
and more. I take the prescribed treatments for mito-
chondrial myopathy and can tell you they do work and
they have been every bit worth the price.
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